$OTLC
Oncotelic Therapeutics, Inc.

2014 Q1 Form 10-K Financial Statement

#000119312514108092 Filed on March 20, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 2012 Q4
Revenue $0.00 $95.00K $40.00K
YoY Change -39.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.240M $4.740M $940.0K
YoY Change 8.77% 1.07% -26.56%
% of Gross Profit
Research & Development $1.387M $3.636M $770.0K
YoY Change 85.92% 3.21% -23.76%
% of Gross Profit
Depreciation & Amortization $4.000K $12.00K $50.00K
YoY Change 33.33% -58.62% 25.0%
% of Gross Profit
Operating Expenses $2.628M $8.375M $1.710M
YoY Change 39.71% 1.79% -25.33%
Operating Profit -$2.628M -$8.280M
YoY Change 39.71% 2.58%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K -$1.000K -$10.00K
YoY Change -96.0% -150.0%
Pretax Income -$2.630M -$8.280M -$1.680M
YoY Change 39.89% 2.48% -28.51%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.630M -$8.277M -$1.680M
YoY Change 39.89% 2.45% -28.51%
Net Earnings / Revenue -8712.63% -4200.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.29 -$4.67 -$1.08
COMMON SHARES
Basic Shares Outstanding 15.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.74M $7.010M $4.950M
YoY Change 442.54% 41.62% -50.35%
Cash & Equivalents $24.74M $7.010M $4.950M
Short-Term Investments
Other Short-Term Assets $41.00K $160.0K $142.0K
YoY Change -90.89% -46.67% -78.81%
Inventory
Prepaid Expenses $368.0K $135.0K
Receivables
Other Receivables
Total Short-Term Assets $25.14M $7.170M $5.243M
YoY Change 401.88% 36.83% -50.77%
LONG-TERM ASSETS
Property, Plant & Equipment $32.00K $40.00K $13.00K
YoY Change 220.0% 300.0% -56.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $102.0K $120.0K $204.0K
YoY Change -40.0% -42.86% -50.24%
TOTAL ASSETS
Total Short-Term Assets $25.14M $7.170M $5.243M
Total Long-Term Assets $102.0K $120.0K $204.0K
Total Assets $25.25M $7.290M $5.447M
YoY Change 387.37% 33.76% -50.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $432.0K $480.0K $416.0K
YoY Change -4.0% 14.29% 60.0%
Accrued Expenses $960.0K $780.0K $490.0K
YoY Change 146.15% 59.18% -75.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.395M $1.250M $901.0K
YoY Change 68.07% 38.89% -60.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.395M $1.250M $901.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.400M $1.250M $900.0K
YoY Change 68.67% 38.89% -60.18%
SHAREHOLDERS EQUITY
Retained Earnings -$241.1M -$225.4M
YoY Change
Common Stock $265.0M $230.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.85M $6.040M $4.546M
YoY Change
Total Liabilities & Shareholders Equity $25.25M $7.290M $5.447M
YoY Change 387.37% 33.76% -50.75%

Cashflow Statement

Concept 2014 Q1 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$2.630M -$8.277M -$1.680M
YoY Change 39.89% 2.45% -28.51%
Depreciation, Depletion And Amortization $4.000K $12.00K $50.00K
YoY Change 33.33% -58.62% 25.0%
Cash From Operating Activities -$2.624M -$7.001M -$1.880M
YoY Change 38.54% -16.0% -32.86%
INVESTING ACTIVITIES
Capital Expenditures $40.00K $10.00K
YoY Change 300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$35.00K -$10.00K
YoY Change 337.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.86M $1.936M
YoY Change 619.21% -41.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.35M 9.095M 530.0K
YoY Change 1247.95% 174.19% 307.69%
NET CHANGE
Cash From Operating Activities -2.624M -7.001M -1.880M
Cash From Investing Activities -35.00K -10.00K
Cash From Financing Activities 20.35M 9.095M 530.0K
Net Change In Cash 17.73M 2.059M -1.360M
YoY Change -4717.19% -140.97% -49.06%
FREE CASH FLOW
Cash From Operating Activities -$2.624M -$7.001M -$1.880M
Capital Expenditures $40.00K $10.00K
Free Cash Flow -$7.041M -$1.890M
YoY Change -15.63% -32.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.06
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
83000 shares
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
8797000
CY2011Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6000
CY2011Q4 us-gaap Cash
Cash
9972000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1746000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1746000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.73
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
143000 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
357000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
304000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
75939000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
901000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
673880
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
79000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
4546000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
229961000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225432000
CY2012Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1309000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5447000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
5243000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
263000
CY2012Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1978000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
135000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72072000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
75939000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
20000
CY2012Q4 us-gaap Assets
Assets
5447000
CY2012Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1593000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
370000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
191000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
33000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
142000
CY2012Q4 us-gaap Cash
Cash
4946000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2012Q4 oxgn Other Miscellaneous Accrued Liabilities Current
OtherMiscellaneousAccruedLiabilitiesCurrent
94000
CY2012Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
181000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5586000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
108000 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2452431 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5586000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.54
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
192000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.68
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5178000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
157000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.56
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.24
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
268000
CY2013Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
458000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
100000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
476000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
154000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
78581000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1251000
CY2013Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
20000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
748036
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
116000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
6043000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244495000
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
CY2013Q4 us-gaap Contractual Obligation
ContractualObligation
710000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238508000
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1406000
CY2013Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
690000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7294000
CY2013Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
100000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
7165000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
434000
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2171000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
74533000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
78581000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2013Q4 us-gaap Assets
Assets
7294000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
CY2013Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1360000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
304000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
93000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
83000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000
CY2013Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
1500000
CY2013Q4 us-gaap Cash
Cash
7005000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
95000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2013Q4 oxgn Percentage Of Discount
PercentageOfDiscount
0.15 pure
CY2013Q4 oxgn Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
11868000
CY2013Q4 oxgn Other Miscellaneous Accrued Liabilities Current
OtherMiscellaneousAccruedLiabilitiesCurrent
188000
CY2013Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
317000
CY2013Q4 oxgn Purchase Commitment Amount Due
PurchaseCommitmentAmountDue
2077000
CY2013Q4 oxgn Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Related Party
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRelatedParty
147145 shares
CY2013Q4 oxgn Clinical Development And Related Commitments
ClinicalDevelopmentAndRelatedCommitments
610000
CY2013Q4 oxgn Clinical Development And Related Commitments Due In Fifth Year And Thereafter
ClinicalDevelopmentAndRelatedCommitmentsDueInFifthYearAndThereafter
CY2013Q4 oxgn Clinical Development And Related Commitments Due In Next Twelve Months
ClinicalDevelopmentAndRelatedCommitmentsDueInNextTwelveMonths
590000
CY2013Q4 oxgn Clinical Development And Related Commitments Due In Second Year
ClinicalDevelopmentAndRelatedCommitmentsDueInSecondYear
20000
CY2013Q4 oxgn Clinical Development And Related Commitments Due In Third Year
ClinicalDevelopmentAndRelatedCommitmentsDueInThirdYear
CY2013Q4 oxgn Clinical Development And Related Commitments Obligation Due In Fourth Year
ClinicalDevelopmentAndRelatedCommitmentsObligationDueInFourthYear
CY2013Q4 oxgn Operating Leases Future Minimum Payments Due In Fifth Year And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFifthYearAndThereafter
CY2013Q4 oxgn Warrants Exchanged For Different Class Of Warrant Value
WarrantsExchangedForDifferentClassOfWarrantValue
1555000
CY2013Q4 oxgn Future Purchase Commitment
FuturePurchaseCommitment
1260000
CY2013Q4 oxgn Purchase Commitment Estimated And Accrued
PurchaseCommitmentEstimatedAndAccrued
162000
CY2013Q4 oxgn Purchase Commitment Non Cancelable Contracts Obligation
PurchaseCommitmentNonCancelableContractsObligation
570000
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15236069 shares
CY2013Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1377412 shares
CY2013Q2 dei Entity Public Float
EntityPublicFloat
5982000
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2452431 shares
CY2013Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.24
CY2009Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1360000
CY2009Q4 oxgn Recorded Capital Loss Carryforward
RecordedCapitalLossCarryforward
4000000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
340.00
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
27000 shares
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-5255000
CY2010Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
7498000
CY2010Q4 us-gaap Cash
Cash
4602000
CY2011Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
6633000
CY2011Q1 oxgn Common Shares Issued In Exchange For Different Class Of Warrants Value
CommonSharesIssuedInExchangeForDifferentClassOfWarrantsValue
4388000
CY2011Q1 oxgn Gain Loss On Exchange Of Warrant
GainLossOnExchangeOfWarrant
690000
CY2011Q1 oxgn Warrant Liabilities Combined Fair Value
WarrantLiabilitiesCombinedFairValue
6633000
CY2011Q1 oxgn Warrants Exchanged For Different Class Of Warrant Value
WarrantsExchangedForDifferentClassOfWarrantValue
1555000
CY2010Q2 oxgn Gross Proceeds From Issuance Of Private Placement
GrossProceedsFromIssuanceOfPrivatePlacement
7500000
CY2010Q2 oxgn Number Of Warrants Series
NumberOfWarrantsSeries
4 Warrant
CY2012Q2 oxgn Commitment To Purchase Number Of Common Stock
CommitmentToPurchaseNumberOfCommonStock
23783 shares
CY2013Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5000000
CY2013Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4192000
CY2013Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5800000
CY2013Q3 oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
CY2011Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.050 pure
CY2012Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083 pure
CY2011Q1 oxgn Number Of Common Stock Shares Issued In Exchange
NumberOfCommonStockSharesIssuedInExchange
38128 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0026 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.12 pure
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M23D
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
931000 shares
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.62
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.42
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11784000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.37
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
70000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
14000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
304.52
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9000
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9653000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-11892000
CY2011 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2222000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-9653000
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8000
CY2011 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-55000
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-956000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5375000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17154000
CY2011 us-gaap Adjustment For Amortization
AdjustmentForAmortization
97000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
851000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5370000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17146000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5291000
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
CY2011 us-gaap Restructuring Charges
RestructuringCharges
1226000
CY2011 us-gaap Depreciation
Depreciation
53000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
851000
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
582676
CY2011 us-gaap Operating Expenses
OperatingExpenses
11892000
CY2011 oxgn Expenses With Issuance Of Common Stock
ExpensesWithIssuanceOfCommonStock
1013000
CY2011 oxgn Issuance Of Common Stock For Initial Commitment Fee In Connection Purchase Agreement
IssuanceOfCommonStockForInitialCommitmentFeeInConnectionPurchaseAgreement
314000
CY2011 oxgn Issuance Of Common Stock In Connection With Private Placement Warrant Exchange
IssuanceOfCommonStockInConnectionWithPrivatePlacementWarrantExchange
5383000
CY2011 oxgn Issuance Of Common Stock Under Atm
IssuanceOfCommonStockUnderAtm
17146000
CY2011 oxgn Reclassification Of Ceff Warrants To Derivative Liability Due To Private Placement Warrants
ReclassificationOfCeffWarrantsToDerivativeLiabilityDueToPrivatePlacementWarrants
3000
CY2013 dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0000908259
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3191 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2803000 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies Domestic
EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
-0.0048 pure
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.01 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.77
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M6D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0095 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.90
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0003 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.00 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M10D
CY2013 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.20 pure
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7001000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.67
CY2013 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
10417 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
107000 shares
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M10D
CY2013 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2014-06-30
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
58000 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M1D
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 12px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company has no significant off balance sheet concentrations of credit risk. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company holds its cash and cash equivalents at one financial institution.</font></p> </div>
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0031 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.38
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0031 pure
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0164 pure
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
40472
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-117000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
33684
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13076000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-8280000
CY2013 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2642000
CY2013 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1345000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-8277000
CY2013 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-20000
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
95000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9097000
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
6295000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
350000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4739000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9095000
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
7998000
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
864000
CY2013 us-gaap Adjustment For Amortization
AdjustmentForAmortization
98000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
679000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2059000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1936000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3636000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7800
CY2013 us-gaap Restructuring Charges
RestructuringCharges
CY2013 us-gaap Depreciation
Depreciation
12000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
679000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
212473
CY2013 us-gaap Operating Expenses
OperatingExpenses
8375000
CY2013 us-gaap License Costs
LicenseCosts
2500000
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4799000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 oxgn Effective Income Tax Rate Reconciliation Capital Loss Limitation
EffectiveIncomeTaxRateReconciliationCapitalLossLimitation
pure
CY2013 oxgn License Agreement Term
LicenseAgreementTerm
P15Y6M
CY2013 oxgn Tax Credit Carryforward Beginning Expiration Year
TaxCreditCarryforwardBeginningExpirationYear
2021
CY2013 oxgn Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0016 pure
CY2013 oxgn Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
864000
CY2013 oxgn Redemption Of Preferred Stock During Period
RedemptionOfPreferredStockDuringPeriod
2802000
CY2013 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2013 oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
CY2013 oxgn Area Of Facility Lease
AreaOfFacilityLease
5275 sqft
CY2013 oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
CY2013 oxgn Due Date From Which Monthly Base Rent Payable
DueDateFromWhichMonthlyBaseRentPayable
2013-07-01
CY2013 oxgn Adjusted Base Monthly Rent Under Facility Lease
AdjustedBaseMonthlyRentUnderFacilityLease
16616
CY2013 oxgn Due Date To Which Monthly Base Rent Payable
DueDateToWhichMonthlyBaseRentPayable
2014-06-30
CY2013 oxgn Effective Income Tax Rate Reconciliation State And Local Rate Change
EffectiveIncomeTaxRateReconciliationStateAndLocalRateChange
-0.0338 pure
CY2013 oxgn Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
0.0000 pure
CY2013 oxgn Expenses With Issuance Of Common Stock
ExpensesWithIssuanceOfCommonStock
72000
CY2013 oxgn Expenses With Private Placement Financing
ExpensesWithPrivatePlacementFinancing
1703000
CY2013 oxgn Increase In Fair Value Of Warrant Liability Over Net Proceeds Received
IncreaseInFairValueOfWarrantLiabilityOverNetProceedsReceived
4933000
CY2013 oxgn Inspection Period For Product Defects
InspectionPeriodForProductDefects
P30D
CY2013 oxgn Issuance Of Common Stock Under Atm
IssuanceOfCommonStockUnderAtm
1936000
CY2013 oxgn Payments To Acquire Property Plant Equipment And Other Assets
PaymentsToAcquirePropertyPlantEquipmentAndOtherAssets
35000
CY2013 oxgn Percentage Of Distribution Revenue On Gross Margin Earned
PercentageOfDistributionRevenueOnGrossMarginEarned
0.20 pure
CY2013 oxgn Per Share Fair Value Of Common Stock
PerShareFairValueOfCommonStock
48
CY2013 oxgn Per Share Fair Value Of Common Stock Exchanged For Warrant
PerShareFairValueOfCommonStockExchangedForWarrant
26.04
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1352000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4690000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3317000
CY2012 us-gaap Adjustment For Amortization
AdjustmentForAmortization
98000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
511000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5026000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3317000
CY2013 oxgn Redemption Of Preferred Stock During Period Value
RedemptionOfPreferredStockDuringPeriodValue
2802000
CY2013 oxgn Deferred Tax Assets Expiry Year
DeferredTaxAssetsExpiryYear
2014
CY2010 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M21D
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0085 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.02 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
-0.2983 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M21D
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0243 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1473000 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.83
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0051 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies Domestic
EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
-0.0001 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.94
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8335000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.48
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
124000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
64000 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0146 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
66.21
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0054 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0701 pure
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
654701
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-464000
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
19179
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8079000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-8072000
CY2012 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
6000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-195000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-8079000
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
156000
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2047000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3523000
CY2012 us-gaap Restructuring Charges
RestructuringCharges
15000
CY2012 us-gaap Depreciation
Depreciation
29000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
511000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
516257
CY2012 us-gaap Operating Expenses
OperatingExpenses
8228000
CY2012 oxgn Effective Income Tax Rate Reconciliation Capital Loss Limitation
EffectiveIncomeTaxRateReconciliationCapitalLossLimitation
pure
CY2012 oxgn Increase Decrease In Fair Value Of Warrants
IncreaseDecreaseInFairValueOfWarrants
6000
CY2012 oxgn Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0103 pure
CY2012 oxgn Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
0.0002 pure
CY2012 oxgn Expenses With Issuance Of Common Stock
ExpensesWithIssuanceOfCommonStock
137000
CY2012 oxgn Issuance Of Common Stock Under Atm
IssuanceOfCommonStockUnderAtm
1270000
CY2012 oxgn Payments To Acquire Property Plant Equipment And Other Assets
PaymentsToAcquirePropertyPlantEquipmentAndOtherAssets
8000

Files In Submission

Name View Source Status
0001193125-14-108092-index-headers.html Edgar Link pending
0001193125-14-108092-index.html Edgar Link pending
0001193125-14-108092.txt Edgar Link pending
0001193125-14-108092-xbrl.zip Edgar Link pending
d650569d10k.htm Edgar Link pending
d650569dex1038.htm Edgar Link pending
d650569dex231.htm Edgar Link pending
d650569dex311.htm Edgar Link pending
d650569dex312.htm Edgar Link pending
d650569dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
oxgn-20131231.xml Edgar Link completed
oxgn-20131231.xsd Edgar Link pending
oxgn-20131231_cal.xml Edgar Link unprocessable
oxgn-20131231_def.xml Edgar Link unprocessable
oxgn-20131231_lab.xml Edgar Link unprocessable
oxgn-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending